Drug Trial News

RSS

Dry powdered measles vaccine triggers no adverse side effects in early human testing

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal Vaccine.

26 Nov 2014

FDA-approved therapy could be effective in older, African American patients with lung cancer

University of Cincinnati researchers have found in a phase-2 clinical trial that a Food and Drug Administration-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy.

26 Nov 2014

Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel against colorectal cancer models

Genes make proteins and proteins tell your body's cells what to do: one talks to the next, which talks to the next, and to the next. Like a game of telephone, researchers call these "signaling pathways". Abnormalities in these signaling pathways can cause the growth and survival of cancer cells. Commonly, mutations or rearrangements of genes in the MAPK signaling pathway create cancer's fast growth, and alterations in the PI3K signaling pathway allow cancer cells to survive into virtual immortality.

26 Nov 2014

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Parent Project Muscular Dystrophy, the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne) and Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases, will collaborate on a benefit/risk study in Duchenne.

25 Nov 2014

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA).

25 Nov 2014

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

Hydroxyurea therapy offers safe, effective disease management of SCA

Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy.

23 Nov 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine.

21 Nov 2014

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

20 Nov 2014

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.

19 Nov 2014

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

18 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world’s leading medical journals, The Lancet Neurology.

18 Nov 2014

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium levels). The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014.

18 Nov 2014

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

18 Nov 2014

Drug combination shows promise in patients with newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

Drug Trial News

Dry powdered measles vaccine triggers no adverse side effects in early human testing

FDA-approved therapy could be effective in older, African American patients with lung cancer

Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel against colorectal cancer models

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Hydroxyurea therapy offers safe, effective disease management of SCA

New drug shows promise against treatment-resistant non-small cell lung cancer

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

TapImmune signs new collaborative research agreement with VGTI Florida

New oral medication shows promise in treating fibromyalgia

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Adding ezetimibe to statin therapy reduces cardiovascular events

Drug combination shows promise in patients with newly diagnosed multiple myeloma

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News